Eli Lilly: FDA Approval for Mounjaro for Cardiovascular Prevention Opens New Billion-Dollar Markets
Reading Time: 2 minutes
Mounjaro and Zepbound drove a revenue growth of 48% to $23.0 billion in the second quarter. The FDA approval on August 28 expands the use of Mounjaro for reducing cardiovascular risks. The medical indication simplifies reimbursement processes and secures long-term market shares. Focus on Incretin Mimetics Drives Revenue Growth The business model of Eli Lilly (LLY) primarily relies on biopharmaceuticals, with cardiometabolic therapies being the current revenue pillar. A key growth trend is the persistently high demand for GLP-1 and GIP...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
